Literature DB >> 16391432

Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns.

Mark R Schleiss1.   

Abstract

Congenital and perinatal infections with cytomegalovirus (CMV) are responsible for considerable short- and long- term morbidity in infants. CMV is the most common congenital viral infection in the developed world, and is a common cause of neurodevelopmental injury, including mental retardation and sensorineural hearing loss (SNHL). Antiviral therapy has been shown to be valuable in ameliorating the severity of SNHL, but CMV disease control in newborns ultimately depends on successful development of a vaccine. Because CMVs are extremely species specific, preclinical evaluation of vaccines must be performed in animal models using the appropriate CMV of the animal being studied. Several small animal models available for CMV vaccine and pathogenesis research are described. The discussion focuses on the guinea pig model because guinea pig cytomegalovirus (GPCMV), which crosses the placenta and causes infection in utero, is uniquely useful. Examination of vaccines in the GPCMV and other nonprimate models should provide insights into the determinants of the host response that protect the fetus, and may help to prioritize potential vaccine strategies for use in human clinical trials related to this important public health problem.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391432     DOI: 10.1093/ilar.47.1.65

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  37 in total

1.  Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.

Authors:  A McGregor; K Y Choi; M R Schleiss
Journal:  Virology       Date:  2010-11-20       Impact factor: 3.616

2.  Human cytomegalovirus infection of human embryonic stem cell-derived primitive neural stem cells is restricted at several steps but leads to the persistence of viral DNA.

Authors:  Jean-Philippe Belzile; Thomas J Stark; Gene W Yeo; Deborah H Spector
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

Review 3.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

4.  Establishment of rat brain endothelial cells susceptible to rat cytomegalovirus ALL-03 infection.

Authors:  Siti-Nazrina Camalxaman; Nazariah Allaudin Zeenathul; Yi-Wan Quah; Hwei-San Loh; Hassan Zuridah; Homayoun Hani; Abdul Rahman Sheikh-Omar; Mohd Lila Mohd-Azmi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-02-22       Impact factor: 2.416

5.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

6.  An Attenuated CMV Vaccine with a Deletion in Tegument Protein GP83 (pp65 Homolog) Protects against Placental Infection and Improves Pregnancy Outcome in a Guinea Pig Challenge Model.

Authors:  Mark R Schleiss; Ryan Buus; K Yeon Choi; Alistair McGregor
Journal:  Future Virol       Date:  2013-12-01       Impact factor: 1.831

7.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

8.  A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection.

Authors:  Megan M Crumpler; K Yeon Choi; Michael A McVoy; Mark R Schleiss
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

9.  An in vitro mouse model of congenital cytomegalovirus-induced pathogenesis of the inner ear cochlea.

Authors:  Michael Melnick; Tina Jaskoll
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2012-12-26

10.  Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Authors:  Mark R Schleiss; K Yeon Choi; Jodi Anderson; Janine Gessner Mash; Martine Wettendorff; Sally Mossman; Marc Van Damme
Journal:  Vaccine       Date:  2013-07-16       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.